Novo Nordisk Wins EU Approval for Higher-Dose Wegovy in Obesity Treatment

The European Union has officially granted regulatory approval for a higher 7.2 mg dose of Novo Nordisk's blockbuster weight-loss medication, Wegovy. This regulatory milestone expands the treatment options available to obesity patients across the European market by providing a new step-up option. The higher dosage is designed to offer clinicians greater flexibility in titration schedules and potentially deliver more significant weight-loss outcomes for patients. By broadening its product portfolio, Novo Nordisk strengthens its dominant position in the rapidly growing global obesity market. Investors view this development as a positive driver for the company's long-term revenue growth and competitive edge in the pharmaceutical sector.